Did Phreesia beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Phreesia year over year?

What is Phreesia's latest dividend and current dividend yield?

What guidance did Phreesia's management provide for the next earnings period?

What factors drove the changes in Phreesia's revenue and profit?

What were the key takeaways from Phreesia's earnings call?

What is the market's earnings forecast for Phreesia next quarter?

What were the key takeaways from Phreesia’s earnings call?

- **Record Financials**: Q3 2026 revenue of $120.3M (+13% YoY), EBITDA margin of 24% (vs. 9% in 2025)
- **Strategic Acquisitions**: $53M AccessOne deal adds $450M receivables book, contributing $7.5M in Q4 2026
- **Growth Drivers**: 
  - Provider financing: 6.5% of 2027 revenue
  - HCP marketing: Double-digit revenue per AHSC growth
  - Voice AI: 53 new AHSCs in Q3
- **Margin Expansion**: 2027 EBITDA guidance implies 450bps margin improvement, driven by operating leverage and cost control

**【CEO Summary Section】**
- Introduced two new growth initiatives: **provider financing (via AccessOne acquisition)** and **HCP (Healthcare Provider) marketing**.
- Provider financing aims to address rising patient financial responsibility, with AccessOne managing $450M in receivables and generating a 4%-12% take rate.
- HCP marketing leverages Phreesia's clinical workflow integration to engage providers during patient visits, targeting a multibillion-dollar digital marketing opportunity.

**【CFO Financial Commentary】**
- **Q3 2026 Results**: 
  - Total revenue: $120.3M (+13% YoY)
  - Adjusted EBITDA: $29.1M (500% YoY growth, 24% margin)
  - Free cash flow: $8.8M (+72% YoY)
- **AccessOne Contribution**: 
  - 80 AHSCs (annualized) and $7.5M revenue in Q4 2026
  - 4%-12% take rate on $450M portfolio, 65%-75% cost structure
- **2027 Outlook**: 
  - Revenue: $545M-$559M (+17%-19% YoY)
  - Adjusted EBITDA: $125M-$135M (+27%-37% YoY)
  - AHSC growth: mid-single digits, revenue per AHSC: double-digit growth

**【Q&A Highlights】**
- **AccessOne Integration**: Requires go-to-market investment, with 15 AHSCs added in Q4 2026
- **Network Solutions Growth**: Driven by voice AI and post-script engagement, with 60%-70% visibility for 2027
- **Margins**: 450bps expansion in 2027, balanced with sales and R&D investments
- **HCP Marketing**: Pilots launching in Q1 2027, targeting incremental pharma budgets

Phreesia, Inc. (PHR) Q3 2026 Earnings Call Transcript

- **$160M AccessOne Acquisition**: Expands TAM to $24B, adds $35M annualized revenue, and strengthens payment solutions with 0% interest plans backed by PNC Bank.
- **Financial Milestone**: First positive net income ($700K) and 19% EBITDA margin, with 4 consecutive quarters of positive free cash flow.
- **VoiceAI Innovation**: Rapid adoption by providers for clinical support and patient engagement, driving Network Solutions TAM expansion.
- **Growth Outlook**: FY2026 EBITDA raised to $87-$92M, supported by 15% revenue growth and cost control.


**【CEO Summary Section】**
- Announced acquisition of AccessOne for $160 million, expanding addressable market by $6 billion in payment solutions and $6 billion in network solutions, increasing total TAM to $24 billion from $10 billion.
- Achieved first-ever positive net income of $700,000, marking a significant financial milestone.
- Named Evan Roberts as President of Provider Solutions and David Linetsky as President of Network Solutions, recognizing their leadership in driving client success.

**【CFO Financial Commentary】**
- Q2 2026 revenue: $117.3 million (15% YoY growth), with 298 new AHSCs YoY and $26,249 revenue per AHSC (7% YoY growth).
- Adjusted EBITDA: $22 million (19% margin), up $16 million YoY; net income: $700,000 (first positive quarter).
- Cash flow: $98.3 million in cash, $14.8 million operating cash flow (up $3.8 million YoY), and $9.0 million free cash flow (up $6 million YoY).
- Updated FY2026 outlook: Revenue $472-$482 million, adjusted EBITDA $87-$92 million (up $2 million at both ends).
- AccessOne expected to contribute $35 million annualized revenue and $11 million EBITDA post-close.

**【Q&A Key Highlights】**
- **AccessOne Integration**: CFO clarified PNC Bank shares risk in payment plans, and cross-sell opportunities with core products will drive growth. Transaction expected to close Q3/Q4 2026.
- **VoiceAI Product**: CEO highlighted rapid adoption, with providers using it for appointment booking, prescription refills, and clinical support, positioning it as a key revenue driver.
- **Network Solutions Growth**: CFO noted 25% QoQ growth in Network Solutions, driven by pharma marketing campaigns and expanded TAM from VoiceAI adoption.
- **AI Strategy**: CEO emphasized monetization through client value, with internal and external AI investments balanced to maintain operational efficiency.
- **Sales & Marketing Efficiency**: CFO noted stable sales expenses with improving productivity, enabling continued investment in product innovation.


Phreesia, Inc. (PHR) Q2 2026 Earnings Call Transcript

- **Revenue Growth**: Q1 2026 revenue up 15% YoY to $115.9M, driven by 70 net new clients and 6% ARPU growth.
- **Profitability**: Adjusted EBITDA of $20.8M (+16.7% YoY), with free cash flow improving $13.7M YoY.
- **AI & Product Expansion**: Medaphine in early stages, AI-driven products like bill pay driving client retention.
- **Cash Deployment**: $90.9M cash on hand, with buyback plan and M&A flexibility for high-ROI opportunities.
- **Client Trends**: Pharma clients shifting spend to high-ROI platforms, providers favoring scaled partners over smaller vendors.

**【CEO Opening Remarks】**
- Emphasized product-led growth strategy, highlighting AI integration across products like appointment readiness and bill pay.
- Noted 4,500+ healthcare services clients and 6% YoY ARPU growth, driven by new product adoption.
- Highlighted strong balance sheet ($90.9M cash) and free cash flow ($7.5M Q1), enabling capital allocation for growth and shareholder returns.

**【CFO Financial Review】**
- Q1 2026 Revenue: $115.9M (+15% YoY), with 70 net new clients QoQ and 346 YoY.
- Adjusted EBITDA: $20.8M (+16.7% YoY), margin 18%.
- Free cash flow positive for 4Q in a row, up $13.7M YoY.
- Updated FY26 Outlook: Revenue $472-482M, EBITDA $85-90M (vs prior $78-88M).

**【Q&A Key Themes】**
1. **Network Solutions Growth**: 15% YoY revenue, driven by pharma clients' ROI focus. Clients titrate campaigns in real-time based on MLR-approved programs.
2. **AI & Product Innovation**: Medaphine (provider search platform) in early innings, with 2025 investments expected to drive future growth.
3. **Capital Allocation**: Share buyback plan authorized for up to 2.5M shares, but no change to opportunistic M&A strategy.
4. **Market Dynamics**: Providers prefer scaled, trusted partners over smaller, VC-backed competitors. Pharma clients prioritize platforms with proven ROI over DTC ads.
5. **Seasonality**: Payment processing revenue peaks Q1 due to deductible resets, flattens in subsequent quarters.
6. **Margins & Efficiency**: Operating expenses flat YoY, reflecting strong cost control and operating leverage.

Phreesia, Inc. (PHR) Q1 2026 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q4 2025 revenue up 15% YoY to $109.7M, driven by 10%+ AHSC expansion and 5%+ revenue per client growth.
- **Cash Flow Turnaround**: Positive free cash flow ($9.2M) for 3rd straight quarter, up $30M YoY from -$20.9M in Q4 2024.
- **AI-Driven Efficiency**: Internal AI tools already improving forecasting accuracy, with plans to expand into client workflows.
- **Network Solutions Momentum**: 50%+ of revenue now from higher-margin subscription/payment processing, up from ~30% in 2023.
- **2026 Outlook**: Target $400M-$482M revenue (+18%-27% YoY), reflecting confidence in pipeline and execution.

**【CEO Opening Remarks】**
- Celebrated 20 years of operations, with the Phreesia platform used in ~14% of U.S. patient visits (~170 million interactions in Q4 2025).
- Highlighted new product launches improving patient/provider experience, with plans to expand availability across existing and new clients.

**【CFO Financial Highlights】**
- Q4 2025 Revenue: $109.7M (+15% YoY), Adjusted EBITDA: $16.4M (15% margin).
- Free Cash Flow: $9.2M (vs. -$10.9M in Q4 2024), Operating Cash Flow: $16.3M (+$19.3M YoY).
- FY 2026 Outlook: Revenue $400M-$482M, EBITDA $78M-$88M, with continued focus on profitable growth and cash generation.

**【Q&A Key Takeaways】**
- **Gross Margin Expansion**: Driven by higher-margin Network Solutions revenue mix, with ~50% of revenue now from subscription and payment processing (vs. lower-margin clearinghouse).
- **Network Solutions Growth**: 170M+ annual visits provide scalable platform, with new products like appointment readiness and postscript engagement driving incremental revenue.
- **AI Adoption**: Internal AI tools for forecasting and workflow automation already delivering value, with plans to integrate into client-facing solutions.
- **Market Dynamics**: Despite macro uncertainty, strong close rates in sales pipeline suggest continued share gains against competitors like Salesforce.
- **Capital Allocation**: Maintain disciplined approach to M&A and organic R&D, with ~$84M cash balance supporting flexibility.

Actual			-0.1	-0.16	-0.17	-0.17	-0.18	-0.24	-0.48	-0.71	-0.9	-0.99	-0.89	-0.76	-0.72	-0.7	-0.68	-0.58	-0.56	-0.35	-0.31	-0.25	-0.11	-0.07	0.01	0.07
Forecast			-0.0943	-0.234	-0.1648	-0.1601	-0.1596	-0.1819	-0.2233	-0.4726	-1.0307	-1.0579	-0.9728	-0.8672	-0.78	-0.7528	-0.7132	-0.6808	-0.5612	-0.4682	-0.3541	-0.2365	-0.1779	-0.1218	-0.0627	-0.0004	0.0649
Surprise	0.00%	0.00%	-6.04%	+31.62%	-3.16%	-6.18%	-12.78%	-31.94%	-114.96%	-50.23%	+12.68%	+6.42%	+8.51%	+12.36%	+7.69%	+7.01%	+4.66%	+14.81%	+0.21%	+25.25%	+12.45%	-5.71%	+38.17%	+42.53%	+115.95%	+17600.00%	0.00%

PHR

PHR fundamentals

PHR Q4 2026 Earnings Preview

Earnings Call

You can ask Aime

PHR

PHR fundamentals

PHR Q4 2026 Earnings Preview

Earnings Call

PHR Earnings Call Summary for Q4/2026Upcoming5:00 PM on Mar 30, 2026

PHR Earnings Call Summary for Q3/20265:00 PM on Dec 8, 2025

PHR Earnings Call Summary for Q2/20265:00 PM on Sep 4, 2025

PHR Earnings Call Summary for Q1/20268:30 AM on May 28, 2025

PHR Earnings Call Summary for Q4/20255:00 PM on Mar 12, 2025

You can ask Aime